peepoInvestment Overview I last provided coverage of Novavax (NASDAQ:NVAX) - the Gaithersburg, Maryland based developer of "innovative vaccines to prevent serious infectious diseases", ahead of the company's Q1 2024 earnings in early May. Frankly, I was not especially optimistic about the company's prospects, although I did not rule out a surprise - I wrote as follows:    The days of wild share price fluctuations and spikes >$100 per share are a long way behind Novavax now - a spike into the double digi ...